Abstract
BackgroundThe extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have